Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of “Moderate Buy” by Analysts

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) have earned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $9.95.

ALLO has been the subject of several research analyst reports. William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. Piper Sandler dropped their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a report on Friday.

Insider Buying and Selling at Allogene Therapeutics

In related news, EVP Zachary Roberts sold 27,199 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total value of $48,414.22. Following the transaction, the executive vice president now owns 488,054 shares in the company, valued at approximately $868,736.12. This trade represents a 5.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Timothy L. Moore sold 14,746 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total value of $25,215.66. Following the sale, the insider now owns 250,713 shares of the company’s stock, valued at approximately $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 52,710 shares of company stock worth $92,125. Corporate insiders own 24.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Cibc World Markets Corp acquired a new position in shares of Allogene Therapeutics during the fourth quarter valued at about $26,000. PAX Financial Group LLC bought a new stake in Allogene Therapeutics during the 4th quarter valued at $27,000. RPO LLC purchased a new position in Allogene Therapeutics during the fourth quarter valued at approximately $31,000. Caption Management LLC purchased a new stake in shares of Allogene Therapeutics in the 4th quarter valued at about $32,000. Finally, Syon Capital LLC bought a new stake in Allogene Therapeutics during the fourth quarter worth about $39,000. 83.63% of the stock is owned by institutional investors.

Allogene Therapeutics Stock Performance

Shares of NASDAQ:ALLO opened at $1.89 on Friday. The stock has a market capitalization of $396.28 million, a P/E ratio of -1.21 and a beta of 1.02. The stock has a 50-day simple moving average of $1.95 and a 200-day simple moving average of $2.33. Allogene Therapeutics has a 1 year low of $1.32 and a 1 year high of $4.89.

Allogene Therapeutics (NASDAQ:ALLO) last released its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06. Analysts predict that Allogene Therapeutics will post -1.28 earnings per share for the current year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).